Genetic and Non-Genetic Therapeutic Strategies for Transthyretin Amyloidosis (ATTR)

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/24

encourage image

There's no tags or description

Looks like no tags are added yet.

25 Terms

1
New cards

What are the two types of transthyretin amyloidosis (ATTR)?

Hereditary ATTR (rare) and Wild type ATTR (common)

2
New cards

What are common symptoms of hereditary ATTR?

Peripheral neuropathy, autonomic neuropathy, and heart failure

3
New cards

What is the primary treatment strategy for ATTR?

Targeting TTR amyloid pathogenesis through reduced production, stabilization, and removal of ATTR.

4
New cards

What gene silencing techniques are used to reduce TTR production?

RNA interference (RNAi) and antisense oligonucleotides (ASO)

5
New cards

What gene editing technology is mentioned for treating ATTR?

CRISPR-Cas9

6
New cards

What is the purpose of stabilizing the TTR tetramer?

To prevent disaggregation into monomers that lead to tissue deposition.

<p>To prevent disaggregation into monomers that lead to tissue deposition.</p>
7
New cards

Name two stabilizers licensed for TTR stabilization.

Tafamidis and Acoramidis

<p>Tafamidis and Acoramidis</p>
8
New cards

How does Tafamidis work?

It binds to TTR at the T4 binding site.

<p>It binds to TTR at the T4 binding site.</p>
9
New cards

What is the expected benefit of Vyndamax for patients?

It is expected to benefit 1,200 Australians with ATTR cardiomyopathy.

10
New cards

What are TTR-binding monoclonals used for?

To enhance phagocytosis by macrophages and remove ATTR from nerves and heart.

<p>To enhance phagocytosis by macrophages and remove ATTR from nerves and heart.</p>
11
New cards

What is NNC6019?

A monoclonal that binds to misfolded TTR for amyloid removal.

12
New cards

What is the significance of siRNA in ATTR treatment?

siRNA was first identified in 1998 and is crucial for RNA interference therapies.

13
New cards

What are the components of small interfering RNAs (siRNAs)?

They are typically 20-25 nucleotides long, double-stranded, with a guide strand and a passenger strand.

14
New cards

How are siRNAs processed in the cell?

They are cleaved from longer dsRNA by DICER and associate with Argonaute proteins to form RISC.

<p>They are cleaved from longer dsRNA by DICER and associate with Argonaute proteins to form RISC.</p>
15
New cards

What is the role of the guide strand in RISC?

It directs RISC to the target mRNA for degradation.

16
New cards

What are some challenges faced by siRNA therapeutics?

Low bioavailability, inability to cross cellular membranes, and endosomal degradation.

17
New cards

What modifications can improve siRNA delivery?

Chemical modifications and the use of lipid nanoparticles (LNP).

18
New cards

What is Patisiran and its significance?

A successful siRNA therapy that reduces circulating TTR levels by over 80%.

19
New cards

What delivery method is used for Patisiran?

Formulated in a second-generation lipid nanoparticle (LNP).

<p>Formulated in a second-generation lipid nanoparticle (LNP).</p>
20
New cards

What is the primary endpoint of the Patisiran Phase 3 trial?

Improvement in the neurological disability score (mNIS+7).

21
New cards

What is Vutrisiran and how does it differ from Patisiran?

A newer siRNA that can be administered subcutaneously with a longer half-life.

22
New cards

What diseases have received FDA approval for siRNA drugs?

Hereditary ATTR neuropathy, acute hepatic porphyria, primary hyperoxaluria, hypercholesterolemia.

23
New cards

What is the significance of the 2020 Nobel Prize in Chemistry?

It recognized the development of CRISPR/Cas9 genetic scissors.

24
New cards

What is the future goal for ATTR therapies?

Effective removal of amyloid fibrils in organs to restore normal function.

25
New cards

What is the potential impact of RNAi and gene editing on heart failure?

They offer potential prevention and cure for a major cause of heart failure in an aging population.